EGFR and neoplasm: The tumor uptake of the zirconium-89 (89Zr)–labeled anti-EGFR mAb imgatuzumab was significantly decreased in mice bearing xenografts of the EGFR shedding cell-line A431 in comparison to the uptake in A549/H441 xenografts with low-EGFR shedding rates113.